Hikma PharmaceuticalsSTU:H5P 80 Net Margin % is 9.70% as of Dec. 2025, which is 17% below its 10-year median of 11.74. GuruFocus rates STU:H5P with a GF Score™ of 80/100 and a GF Value™ of €24.42 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 956 Drug Manufacturers companies, Hikma Pharmaceuticals ranks better than 70.5% on this metric.
The historical rank and industry rank for Hikma Pharmaceuticals's Net Margin % or its related term are showing as below:
STU:H5P'
s Net Margin % Range Over the Past 10 Years
Min: -43.54 Med: 11.74 Max: 22.02
Current: 11.99
STU:H5P's Net Margin % is ranked better than 70.5% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs STU:H5P: 11.99
Hikma Pharmaceuticals (STU:H5P) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Hikma Pharmaceuticals Net Margin % Related Terms
Hikma Pharmaceuticals Net Margin % Historical Data
* Premium members only.
The historical data trend for Hikma Pharmaceuticals's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:H5P vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals (STU:H5P) has a Net Margin % of 9.70% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Hikma Pharmaceuticals and its competitors. This is 17% below median its historical median of 11.74. According to the industry distribution chart, Hikma Pharmaceuticals ranks #282 out of 956 companies in the Drug Manufacturers industry, placing it in the top 29.5%.
Is Hikma Pharmaceuticals' Net Margin % too high?
Hikma Pharmaceuticals' current Net Margin % of 9.70% is 17% below median its 10-year median of 11.74. The Drug Manufacturers industry median Net Margin % is 5.56. Hikma Pharmaceuticals' value of 9.70% is 74.5% above this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #282 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hikma Pharmaceuticals has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #282 out of 956 companies for Net Margin %. This puts Hikma Pharmaceuticals in the upper half of its industry. The industry median Net Margin % is 5.56. Hikma Pharmaceuticals' value of 9.70% is 74.5% above this benchmark. While the company's 10-year median is 11.74 vs. the industry median of 5.56, Hikma Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current Net Margin % of 9.70% is 74.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Hikma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current Net Margin % is 9.70%, which is 17% below median its own 10-year median of 11.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (STU:H5P) is currently considered Modestly Undervalued. The stock's GF Value™ is €24.42, compared to a current price of €17.74 — trading 27.4% below its estimated fair value. The current Net Margin % is 9.70%, which is 17% below median its 10-year median of 11.74 and 74.5% above the Drug Manufacturers industry median of 5.56. Hikma Pharmaceuticals' overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Hikma Pharmaceuticals (STU:H5P), the current Net Margin % is 9.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (STU:H5P) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of €17.74 is trading 27.4% below its estimated GF Value™ of €24.42.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for STU:H5P:
Net Margin %: 9.70% (17% below median its 10-year median of 11.74)
GF Value™: €24.42 vs. price of €17.74 (27.4% below fair value)
Industry Position: 74.5% above the Drug Manufacturers median (#282 of 956)
No single metric tells the full story. See the STU:H5P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
80GF Score
Get the complete analysis for STU:H5P
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:H5P has been successfully added to your 
